Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.India-based Glenmark Pharmaceuticals has secured regulatory approval for the manufacturing and marketing of antiviral drug Favipiravir under the brand name FabiFlu to treat mild to moderate Covid-19.
The approval, granted under an accelerated process, marks the first authorisation for oral Favipiravir in India for this indication.
Since 2014, Favipiravir holds approval in Japan to treat new or re-emerging influenza virus infections. In cells, the drug is converted into an active phosphoribosylated form (favipiravir-RTP), which is identified by viral RNA polymerase as a substrate, in turn blocking RNA polymerase activity..